Recent Progress in Radiosensitive Nanomaterials for Radiotherapy-Triggered Drug Release

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Radiotherapy

Background:

• Radiotherapy-induced drug release offers unique advantages for cancer treatment, including high tissue penetration and spatiotemporal control.
• Current limitations include the high X-ray doses required for prodrug activation, hindering clinical application.
• Nanomaterials present a solution for radiotherapy sensitization and multimodal therapy integration.

Purpose of the Study:

• To review the design principles of X-ray-responsive chemical bonds for controlled drug release.
• To summarize strategies for catalytic radiosensitization using nanomaterials.
• To discuss the progress and clinical translation challenges of X-ray-responsive nanoradiosensitizers.

Main Methods:

• Review of literature on X-ray-responsive chemical bonds and nanoradiosensitizers.
• Analysis of catalytic radiosensitization mechanisms.
• Exploration of integrated multimodal therapies with nanoradiosensitizers.

Main Results:

• X-ray-responsive nanoradiosensitizers enable controlled drug release and enhanced radiotherapy efficacy.
• Catalytic radiosensitization by nanomaterials amplifies therapeutic effects.
• Integration with chemotherapy, photodynamic therapy, immunotherapy, and other modalities shows significant potential.

Conclusions:

• X-ray-responsive nanoradiosensitizers are crucial for advancing personalized cancer therapy.
• Further research is needed to overcome challenges for clinical translation.
• These strategies promise accurate and effective cancer treatment in the near future.